Myomo, Inc.
AMEX:MYO · New York Stock Exchange American
-$0.13 today
Vol 0.69M · Avg 0.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-136.6%
avg -97.9%
ROIC
-46.8%
avg -152.4%
ROA
-40.3%
avg -112.3%
Analysis
ROA is currently the strongest return metric at -40.3% versus its period average of -112.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul R. Gudonis | President, Chief Executive Officer & Chairman | $601,111.00 | — | 71 | $1.28M | 3.31% |
David A. Henry | Chief Financial Officer | $398,875.00 | — | 65 | $424,155.00 | 1.10% |
Harry Kovelman | Chief Medical Officer | $369,309.00 | — | 67 | $90,541.00 | 0.23% |
Micah J. Mitchell | Chief Commercial Officer | $317,391.00 | — | 50 | $93,888.00 | 0.24% |
Malcolm G. Bock | Vice President of Engineering & Product Strategy | — | — | — | — | — |
Galina Shtivelman | Senior Director of Human Resources | — | — | — | — | — |
Kathy Sawyers | Sr. Director of Clinical Outcomes | — | — | — | — | — |
Colin Anderson | Global Director of Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
16
$602,205.11
Sells
3
$109,928.24
Net Sentiment
+$492,276.87
Net buying
Most Active
KIRK THOMAS F
9 transactions
1–10 of 19
Analysis
Insiders reported 16 buys worth $602,205.11 and 3 sells worth $109,928.24 over the last 12 months. That adds up to net buying of $492,276.87. KIRK THOMAS F was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +52.5% | +35.8% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +52.5% over three years. Forward estimates point to Revenue at +35.8% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
electroCore, Inc.
NASDAQ:ECOR
$67.78M
Precision Optics Corporation, Inc.
POCI
$44.90M
MIRA Pharmaceuticals, Inc.
MIRA
$40.43M
Milestone Scientific Inc.
MLSS
$30.39M
NeuroOne Medical Technologies Corporation
NMTC
$27.85M
IGC Pharma, Inc.
IGC
$27.70M
Hyperion DeFi, Inc.
HYPD
$17.02M
Modular Medical, Inc.
MODD
$8.88M
Nexalin Technology, Inc.
NXL
$8.03M
Vicarious Surgical Inc.
RBOT
$1.60M
Who manages MYO?
Myomo, Inc. (MYO) lists 8 active executives. The top listed executive is Micah J. Mitchell, Chief Commercial Officer.
Are MYO insiders buying or selling?
Recent insider activity shows net buying of $295,131.15.
Explore More
Continue the stock analysis
Jump to another research area for this company.